2. Academic Validation
  3. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

  • Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300.
R Suzuki 1,  T Hideshima 1,  N Mimura 1,  J Minami 1,  H Ohguchi 1,  S Kikuchi 1,  Y Yoshida 1,  G Gorgun 1,  D Cirstea 1,  F Cottini 1,  J Jakubikova 1,  Y-T Tai 1,  D Chauhan 1,  P G Richardson 1,  N C Munshi 2,  T Utsugi 3,  K C Anderson 1
Affiliations

Affiliations

  • 1 Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 2 VA Boston Healthcare System, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 3 Tsukuba Research Center, TAIHO PHARMACEUTICAL CO. LTD., Tsukuba, Japan.
PMID: 25306900 DOI: 10.1038/leu.2014.300
Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15785
    99.31%, HSP90α/HSP90β Inhibitor
    HSP